Randomized Controlled Trial To Evaluate Efficacy And Safety Of The Polyvalent Anti-scorpion Venom Serum Of Birmex Versus Other Commercial Venom Serum In Children Population
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Enrollment
- 120
- Locations
- 2
- Primary Endpoint
- Resolution of signs and symptoms of scorpion envenomation
Study Overview
Brief Summary
The morbidity associated with scorpion sting intoxication presents an endemic pattern in the country, where there are highly venomous species of scorpions so the scorpion sting intoxication (IPPA) is considered a medical emergency.
On the other hand, there is scarce scientific literature from different controlled studies evaluating anti-scorpion serum, considering clinical severity scales, lab results and their safety. The aim of this study is to compare the efficacy and safety of scorpion sting treatment, using two sera, one produced by Birmex versus Alacramyn ® (Bioclon).
Detailed Description
We consider relevant conduct this study because the poisoning scorpion bite represents a public health problem.
This is a randomized clinical trial, which included 120 subjects of both sexes aged 0 and 15 years old and residents of the state of Guanajuato, divided into 2 groups: 60 patients received antiscorpion serum of Birmex and 60 patients receive other commercial serum (Alacramyn).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Masking
- Triple (Participant, Care Provider, Investigator)
Eligibility Criteria
- Ages
- 1 Year to 15 Years (Child)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Scorpion sting
- •Age 1 to 15 years
- •Signing an informed consent (signed by parent or guardian)
- •Being residents of the state of Guanajuato
Exclusion Criteria
- •Previous treatment with gamma globulin or immunoglobulin
- •Blood transfusion at any stage of life
- •Patients treated with drugs that interact with anti-scorpion serum
- •History or history of sensitivity or intolerance to anti-scorpion serum or horse products
- •Any immunodeficiency
- •Patients who have participated in a research protocol in the previous month.
Outcomes
Primary Outcomes
Resolution of signs and symptoms of scorpion envenomation
Time Frame: after treatment (expected average of 12 hrs)
Secondary Outcomes
- Evaluate the adverse events in every treated child(inmediately after treatment and until 5 days later)